Investor Relations

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine. For more information visit www.dynavax.com

Events & Presentations


All events & presentations »

E-Delivery of Stockholder Communications


Beneficial stockholders
Registered stockholders